ISL
VNDA icon

Ingalls & Snyder LLC’s Vanda Pharmaceuticals VNDA Stock Holding History

Ingalls & Snyder LLC’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-85,900
Closed -$694K – 358
2013
Q2 		$694K Buy
+85,900
New +$578K 0.04% 196

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ingalls & Snyder LLC's VNDA Position: Q3 2013 in Review

Ingalls & Snyder LLC sold out of Vanda Pharmaceuticals (VNDA) in Q3 2013, closing a stake of 85,900 shares — an estimated $694K sold.

Ingalls & Snyder LLC first reported a position in VNDA in Q2 2013 and held it in 1 quarter. The position peaked at $694K in Q2 2013. 99 funds tracked by Wall St. Rank hold VNDA as of Q3 2013.

  • Ingalls & Snyder LLC reported no remaining Vanda Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 85,900 Vanda Pharmaceuticals shares in Q3 2013, an estimated $694K.
  • Ingalls & Snyder LLC first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Ingalls & Snyder LLC's Vanda Pharmaceuticals position peaked at $694K in Q2 2013.
  • 99 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2013.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2013, filed 12 Nov 2013.